In order to determine the activity of endogenous prolactin, we evaluated the effect of the 21 competitive prolactin receptor antagonist ∆1-9-G129R-hPRL in vivo, using transgenic mice that 22 constitutively and systemically express this antagonist. The weight of the pituitary gland and the 23 anterior pituitary proliferation index, determined by BrdU incorporation, were higher in 24 transgenic mice expressing the antagonist than in wild type littermates. In addition, blockade of 25 prolactin receptor in vitro by ∆1-9-G129R-hPRL increased proliferation and inhibited apoptosis 26 of somatolactotrope GH3 cells and of primary cultures of male rat anterior pituitary cells 27 including lactotropes. These results suggest that prolactin acts as an autocrine/paracrine 28 antiproliferative and proapoptotic factor in the anterior pituitary gland. 29
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In addition, anterior pituitary expression of long isoform of prolactin receptor, measured by real 30 time PCR, increased about 10-fold in transgenic mice expressing the prolactin receptor 31 antagonist, whereas only modest increase of S3 short isoform expression was observed. These 32 results suggest that endogenous prolactin may regulate its own biological actions in the anterior 33
pituitary by inhibiting the expression of the long isoform of the prolactin receptor. 34
Introduction 40
Anterior pituitary expresses prolactin receptors (PRLR) [20, 26] and hence prolactin (PRL) 41 secreted by lactotropes could exert autocrine or paracrine actions on anterior pituitary cells. 42
Although PRL inhibits its own secretion mainly by increasing dopaminergic activity at the 43 hypothalamus, a short-loop regulation of PRL secretion at lactotrope level has been proposed [6, 44 13] . In fact, it has been observed that PRL inhibits its own expression in lactotropes [9] . 45 PRL acts as a proliferative factor in some tissues such as mammary gland, prostate and 46 lymphoid cells [11] but exerts proapoptotic actions in others, such as luteal cells [12] and hair 47 follicles [10] . Although older studies using in vitro cell cultures suggested that PRL could act 48 as a growth factor for anterior pituitary cells [15, 17] , more recent investigations involving 49 genetically-modified mouse models actually achieved opposite conclusions as lack of PRL 50 activity in PRL knockout mice (PRL-/-) and PRLR knockout mice (PRLR-/-) was shown to lead 51 to pituitary hyperplasia and tumor development [8, 27] . Also, it has been shown that exogenous 52
PRL decreases in vitro lactotrope proliferation in D2R knockout mice (D2R-/-) [27], suggesting 53
that PRL may regulate the size of the population of anterior pituitary cells, particularly 54 lactotropes. However, the physiological role of endogenous PRL in anterior pituitary cell 55 renewal remains unclear. 56
Various isoforms of PRLR have been reported, referred to as long, short and, in humans, 57 intermediate PRLR. These isoforms are produced by alternative splicing and differ in the length 58 of their intracellular domain, which determines the characteristics of their signaling. The long 59 isoform of the PRLR (PRLR long ) leads to activation of different pathways, such as Jak2/STAT, 60 MAPK, Src [11] or PI3K/Akt [22] , whereas the short isoform (PRLR short ) phosphorylates Jak2 61 and activates MAPK and PI3K pathways without recruiting STAT proteins . [5, 11] PRLR 62 isoforms not only homodimerize but also heterodimerize and it has been proposed that PRLR short 63 can act as a dominant negative of PRLR long activation [5] . Thus, the relative amount of different 64 PRLR isoforms expressed in a tissue may explain different PRL actions [6] . In this respect, PRL 65 modulates its activity in target cells by inducing the internalization and degradation of its own 66 receptor [29] and by regulating the expression of PRLR isoforms [7, 28, 30] . 67
The evaluation of PRL actions in anterior pituitary has been hampered by the fact that the 68 hormone is constantly present in the system, which can lead to misinterpretation of experimental 69 data obtained by the addition of exogenous PRL [27] . In addition, various isoforms of PRL have 70 been proposed to exert opposite effect on pituitary cells, further complicating the picture [17] . 71 Therefore, in order to determine the actual effects of secreted PRL in anterior pituitary, it is 72 necessary to inhibit its activity. The development of a pure PRLR antagonist provided a newtool for the study of the role of PRL functions [4, 13] . Δ-1-9-G129-hPRL is a competitive 74 antagonist that forms a non-functional complex with PRLR. It has been assayed in several in 75 vitro systems [13, 18] and was recently demonstrated to inhibit in vivo actions of transgenic 76 PRL specifically expressed in prostate tissue, thereby preventing the development of prostate 77 tumors [25] . 78
In the present study we evaluated the effect of endogenous PRL on cell renewal and expression 79 of PRLR isoforms in the anterior pituitary gland. We used transgenic mice systemically 80 expressing Δ1-9-G129R-hPRL as a tool to evaluate the physiological role of endogenous PRL 81 in vivo and Δ1-9-G129R-hPRL to antagonize the effects of PRL released by anterior pituitary 82 cells in vitro. 83
84

Materials and Methods 85
Drugs 86
All drugs, media and supplements were obtained from Sigma (St. Louis, MO, USA) except fetal 87 bovine serum (Natocor, Argentina), amphotericin B, essential aminoacids and gentamicin, 88 below. Recombinant Δ1-9-G129R-hPRL was obtained as previously described [4] . 95
Animals 96
This study was approved by the Comité Régional d'Éthique pour l'Expérimentation Animale, 97
Ile-de-France, Université Paris Descartes, and the Institutional Animal Care and Use Committee 98 of the School of Medicine, University of Buenos Aires. Mice and rats were housed in controlled 99 conditions of light (12-hour light-dark cycles) and temperature (20-25 ºC), and were fed ad 100 libitum. Male Δ1-9-G129R-hPRL transgenic mice systemically expressing Δ1-9-G129R-hPRL 101 (TG) were generated on BALB/c-J background as previously described [25] Medium supplemented with 10 µl/ml MEM amino acids, 2 mM glutamine, 5.6 µg/ml 112 amphotericin B and 25 µg/ml gentamicin (DMEM) and 10% fetal calf serum previously treated 113 with 0.025% dextran-0.25% charcoal to remove steroids (FCS). One hundred thousand cells 114 were seeded onto coverslides in 24-well tissue culture plates for BrdU incorporation and 115 TUNEL studies. For BrdU incorporation assay, cells were incubated in the same medium 116 containing 10% FCS for 24 h and then incubated in the same medium containing PRLR 117 antagonist Δ1-9-G129R-hPRL (5 µg/ml) for 8 h. Six h before fixation, BrdU (200 µM) was 118 added to culture media. For apoptosis and cell cycle evaluation, 1.5 x 10 5 cells/ml/well were 119 incubated for 24 h in supplemented DMEM without FCS and then incubated in the same 120 medium containing ∆1-9-G129R-hPRL (5 µg/ml) for 8 h. 
Flow cytometry 178
GH3 cells were harvested with 0.05% trypsin-EDTA. Cells were washed with PBS, 179 resuspended in 300 µl PBS-0.1% BSA and fixed with 5 ml of 70% ice-cold methanol by gentle 180 vortexing for 30 min at -20 °C. Then, 5 ml of PBS-0.1% BSA were added to each tube. After 181 centrifugation, DNA was stained with propidium iodide (PI, 50 µg/ml) in PBS containing 182 ribonuclease (10 µg/ml) for 20 min at 37 °C. Fluorescence intensity of ≥6,000 gated cells/tube 183 was analyzed by flow cytometry using a FACScan (Becton Dickinson). Cells with a PI staining 184 intensity lower than the G0/G1 peak were considered hypodiploid. Analysis of DNA content 185 and determination of Sub G0/G1 (hypodiploid cells), G0/G1, S and G2/M-phases of cell cycle 186 were performed using WinMDI 98 and Cylcherd 1.2 softwares. 187
RNA extraction and Real-Time PCR 188
Anterior pituitaries were extracted, washed in RNAeasy Solution (Qiagen Inc., Santa Clarita, 189 CA, USA) and immediately frozen in liquid nitrogen. RNA was extracted using RNAeasy 190
Micro Kit (Qiagen) following the manufacture's protocol. Briefly, frozen anterior pituitaries 191 were homogenized using a cold mortar and pestle and placed in 350 μl of RTL lysis buffer 192 (Qiagen) containing β-mercaptoethanol, re-homogenized with a needle and centrifuged. The 193 supernatant was washed with 70% ethanol, centrifuged, and transferred onto an RNAeasy spin 194 column (Qiagen). RNA was collected with 14 μl RNAse-free water and stored at -80 ºC. 195
Reverse transcription was performed using SuperScript II Reverse Transcriptase according to 196 the manufacturer's protocol. One hundred twenty five ng of total RNA were reverse transcribed. 197
After incubation for 5 min at 65 ºC with 1 µl oligo (dT) and 1 µl of dNTP Mix, RNA samples 198 were incubated for 2 min at 42 ºC with a mix containing DTT and RNAse OUT (Invitrogen). (ECD) and reverse primers directed specifically to intracellular domains (ICD) of mouse 204 PRLR long , S1, S2 or S3 PRLR short isoforms, and forward and reverse primers directed to 205 cyclophilin were used ( the Ct values for each PRLR isoform and cyclophilin. In Table 2 , the percentage of expression 218 of each PRLR isoform was calculated relative to the expression of total PRLR in WT or TG 219 mice. In Fig. 7 , data for each PRLR isoform mRNA were expressed relative to PRLR 220 expression in WT mice. 221
Statistical Analysis 222
In vivo experiments 223
BrdU positive cells were counted in 4 random-selected slices from each animal. To study the action of endogenous PRL in anterior pituitary cell renewal, we evaluated the 245 effect of PRLR antagonist ∆1-9-G129R-hPRL in vivo, using transgenic mice that constitutively 246 and systemically express this antagonist [25] . WT and TG mice were injected with BrdU and 247 euthanized 24 h later. Rates of apoptosis and mitosis in the anterior pituitary were assessed. 248
Although body weight remained unchanged, the weight of the pituitary gland in TG mice was 249 25% higher than in WT mice (Fig 1A and B) . Microscopic observation of tissue sections 250 suggested that this increase was due to anterior pituitary gland hyperplasia (Fig 1C) . In fact, the 251 anterior pituitary proliferation index (% of BrdU-positive cells, detected by 252 immunofluorescence) was significantly higher in TG mice than in WT mice ( Fig. 2A) . We 253 observed no changes in apoptotic rate in pituitaries from TG mice (Fig. 2B) . The increase in 254 cell proliferation resulting from inhibition of PRLR signaling by the presence of ∆1-9-G129R-255 hPRL supports an antiproliferative role of endogenous PRL in the anterior pituitary gland. 256
Effect of PRLR antagonism on proliferation and apoptosis of GH3 somatolactotropes cell line 257 and anterior pituitary cells in culture. 258
Transgenic mice expressing the PRLR antagonist ∆1-9-G129R-hPRL were reported to have 259 normal PRL serum levels [25] , suggesting no profound alteration of the dopaminergic tone. 260
Consequently, we hypothesized that the increased cell proliferation observed in anterior 261 pituitaries of these mice was more likely to reflect a direct effect of PRLR antagonism than a 262 reduction of the inhibitory dopaminergic tone. To explore this hypothesis, we investigated the 263 effect of the PRLR antagonist on GH3 cells, a somatolactotrope cell line that constitutively 264 releases PRL [19] . In order to inhibit activation of PRLR by endogenous PRL secreted into the 265 culture medium, GH3 cells were incubated with or without ∆1-9-G129R-PRL (5 µg/ml) for 8 h. 266
Six hours before fixation, BrdU was added to the culture medium. The percentage of BrdU-267 positive cells (detected by immunofluorescence) increased under treatment with the PRLR 268 antagonist (Fig 3) . In other experiments we evaluated the effect of ∆1-9-G129R-hPRL on GH3 269 cell cycle progression using flow cytometry. The percentage of cells in the S-phase increased 270 when PRL effect was antagonized by ∆1-9-G129R-hPRL, whereas the proportion of cells in the 271 other phases of the cell cycle was not modified by the antagonist (Fig. 4) . We also studied the 272 effect of the PRLR antagonist on the apoptosis of GH3 cells. Cells were incubated with or 273 without ∆1-9-G129R-hPRL for 8 h. Apoptosis was evaluated by TUNEL method and flow 274 cytometry (as percentage of cells with hypodiploid DNA content). We observed a reduction in 275 apoptosis when GH3 cells were incubated in the presence of the PRLR antagonist (Fig. 5) . 276
The effect of endogenous prolactin on anterior pituitary cell renewal was also confirmed using 277 primary cultures. The blockade of PRLR by ∆1-9-G129R-hPRL (5 µg/ml, 8 h) induced both an 278 increase in BrdU-positive ( Fig 6A) and a reduction in TUNEL-positive (Fig 6D) anterior 279 pituitary cells. PRL-immunostaining (Fig. 6C, F) revealed that lactotropes were affected by 280 PRLR signaling blockade. Also, a subpopulation of PRL-negative cells was responsive to PRLR 281 antagonist. Taken together, these results suggest that PRL released into the medium acts as a 282 proapoptotic and antiproliferative factor in anterior pituitary cells, including lactotropes. 283
Effect of PRLR antagonism on the expression of PRLR isoforms in the anterior pituitary 284
Anterior pituitaries from WT and TG mice expressing ∆1-9-G129R-hPRL were harvested and 285 processed for RNA extraction. Quantitative RT-PCR was performed using specific primers for 286 long or short (S1, S2, S3) PRLR isoforms. The main isoform expressed in the anterior pituitary 287 from WT or TG mice was PRLR long . The expression of S1 PRLR short was not detected in the 288 anterior pituitary of any genotype ( Table 2 ). The presence of the PRLR antagonist modified the 289 expression of PRLR long and S3 PRLR short isoforms. PRLR long expression increased about 10-fold 290 in the presence of PRLR antagonist, whereas S3 PRLR short expression increased only modestly 291 (Fig. 7) . The S2 and S3 PRLR short isoforms combined represent about 8% of total PRLR 292 expression in WT mice, whereas this proportion decreased to <1% in the presence of the PRLR 293 antagonist (Table 2) . Taken together, these results suggest that PRL inhibits the expression of 294 the PRLR long isoform in the anterior pituitary. 295
Discussion 296
In the present report we show that antagonizing PRLR expressed in pituitary cells using a pure 297 PRLR antagonist devoid of residual agonistic activity leads to increased cell proliferation and 298 decreased apoptosis. This study strongly suggests that endogenous prolactin naturally secreted 299 by anterior pituitary cells exerts autocrine/paracrine antiproliferative and proapoptotic effects. It 300 was suggested that lactotrope hyperplasia and pituitary tumor development observed in D2R-/-301 mice could be due to the high circulating PRL levels observed in these animals. Hence, PRL 302 would act as an autocrine proliferative factor for anterior pituitary cells, particularly lactotropes 303 [16, 17, 26] . Contrary to this hypothesis, observations in PRL-/-mice indicated that PRL is not 304 necessary for the onset or progression of pituitary hyperplasia, and that the lack of the dopamine 305 inhibitory signal is the primary factor inducing abnormal lactotrope growth in these KO mice 306
[8]. However, the fact that double knockout mice lacking both PRLR and D2R exhibited further 307 increased pituitary weight compared to single knockouts argued for a dopamine-independent 308 control of pituitary growth by PRL [27] 309
We observed that the inhibition of PRLR activation in ∆1-9-G129R-hPRL TG mice increased 310 anterior pituitary cell proliferation about 15-fold. Dopaminergic control of lactotrope function 311 involves inhibition of lactotrope proliferation [2] and induction of apoptosis through D2 312 receptor activation [23] . It could be speculated that functional inhibition of hypothalamic PRLR 313 in these TG mice could decrease dopamine release to the portal system leading to a reduction in 314 dopaminergic inhibitory activity at the pituitary level. However, contrary to what was reported 315
for PRLR -/-mice, 6 month-old ∆-1-9-G129R-hPRL mice present no clear increase in serum PRL 316 levels [25] , suggesting that the dopaminergic tone is not profoundly altered in these mice. An 317 incomplete blockade of PRLR at the hypothalamic level in male TG mice may lead to the 318 absence of significant variations in serum PRL at the age studied. Accordingly, studies 319 involving primary cultures of rat hypothalamic cells showed that a small population of cells 320 positive for the dopamine synthesizing enzyme tyrosine hydroxylase were resistant to very high 321 concentrations of PRLR antagonist [18] . Hence, the inhibition by the antagonist of a direct 322 action of PRL at the pituitary level could explain the effects reported in this study for TG mice. 323
In fact, our in vitro studies show direct effects of the PRLR antagonist on GH3 cells as well as 324 on normal anterior pituitary cells and lactotropes, increasing proliferation and reducing 325 apoptosis. These observations suggest that pituitary PRL regulates anterior pituitary cell 326 turnover via autocrine/paracrine mechanisms. Although we observed no change in apoptosis of 327 anterior pituitaries from ∆1-9-G129R-hPRL TG mice, our in vitro experiments indicate that 328 PRL exerts a proapoptotic action on anterior pituitary cells, suggesting that this effect 329 contributes to the role of PRL in anterior pituitary cell renewal. The failure to detect in vivo 330 increased apoptosis in the presence of PRLR antagonist could be due to the low apoptotic rate of 331 pituitary gland and the rapid removal of apoptotic bodies by neighboring cells [21] . 332
Alternatively, as ∆1-9-G129R-hPRL acts in a competitive manner to prevent PRL from binding 333 its receptor, the antagonist/agonist molar ratio existing inside the pituitary of TG mice may be 334 limiting regarding the inhibitory effect that could be achieved by the antagonist. Taken together,these observations suggest that the increase in pituitary weight observed when PRLR signaling 336 is reduced in these TG mice would be a consequence of the decrease of antiproliferative and 337 proapoptotic actions exerted by pituitary PRL in anterior pituitary cells. In this respect, direct 338 comparison of pituitary hypertrophy in our mice versus age-matched PRLR knockout (in which 339 PRLR signaling is totally abolished) could not be made since Schuff et al reported data for 340 animals of one year of age and older [27] . Although paracrine or indirect effects involving 341 other PRL-regulated factors as previously proposed [27] cannot be completely ruled out, the 342 response of lactotropes to the inhibition of PRLR signaling supports the hypothesis that this 343 hormone acts primarily as an autocrine factor on lactotropes. In addition, PRL also affects the 344 turnover of other anterior pituitary cell types. 345
The ultimate effects of PRL on its target tissues depend on the type of PRLR isoforms that are 346 expressed, since they display different abilities to trigger intracellular signaling pathways. Our 347 study indicates that both long and short PRLR isoforms are present in anterior pituitary from 348 male mice, and that the isoform mainly expressed is the long form of the PRLR, as Nagano et al 349 reported in female rat pituitary [20] . PRL has been shown to inhibit its own action by various 350 mechanisms including reduction of its own expression [9] , negative regulation of intracellular 351 signaling [1] and PRLR internalization [29] . In the presence of PRLR antagonist, we noticed an 352 increase of PRLR long mRNA expression suggesting that PRL is able to down regulate its own 353 activity in the anterior pituitary gland by reducing PRLR expression, as previously shown in 354 other tissues [7] . 355
In female rats, the anterior pituitary cell turnover that takes place at each estrous cycle is a 356 highly regulated process in which several factors were demonstrated to participate [32] . A peak 357 of proliferation occurs at estrus whereas the highest rate of apoptosis is observed at proestrus 358 [14, 31] [14] . PRL plasma levels are relatively constant along the estrous cycle, except during 359 proestrus, when an abrupt increase in its secretion occurs, as a result of high circulating estrogen 360 levels [11] . As the peak of PRL occurs when the rate of apoptosis is the highest, the 361 proapoptotic and antiproliferative effects of PRL observed in the present study could be 362 involved in the control of the cyclic changes in anterior pituitary cell renewal that occurs in each 363 estrous cycle in females. The role and mechanisms of action of PRL in regulating the plasticity 364 of anterior pituitary gland in female rodents is under investigation by our group. 365
In conclusion, the present study indicates that PRL could be involved in the maintenance of Expression of PRLR isoforms in anterior pituitary gland from WT and TG mice expressing ∆1-556 9-G129R-PRL. Real Time RT-PCR was performed using specific primers for the PRLRs long 557 and short (S1, S2, S3) isoforms. Each column represents the relative increment ± SEM of 558 PRLR long , S2 PRLR short or S3 PRLR short isoform expression compared to each isoform in WT 559 mice. (n=5-6 animals/group) **p<0.01, *p< 0.05 Student t test. 560
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